Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan(®): a systematic review and meta-analysis.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1 receptor agonist/glucose-dependent insulinotropic polypeptide (GLP-1 RA/GIP) compounds just picked up another win in the lab. A new meta-analysis crunched data from nine trials, covering over 550 patients with metabolically associated fatty liver disease (MASLD). The question: can these research peptides actually make a dent in liver stiffness and fat buildup, measured non-invasively with Fibroscan?
Intern Emerg Med
by Berardicurti A, D'Andrea S, Cipollone F et al.
“Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan(®): a systematic review and meta-analysis. Berardicurti A(1), D'Andrea S(2), Cipollone F(3), Berardicurti O(4), Schiavone C(1), Boccatonda A(5). Author information: (1)Department of Medicine and Science of Aging, University Gabriele d'Annunzio Chieti-Pescara, Chieti, Italy. (2)Endocrinology Outpatient Clinic, Department "Area Peligno-Sangrina", ASL 1 Abruzzo, L'Aquila, Italy. dandrea.settimio@outlook.com. (3)Department of Medicine and Aging Science, Institute of "Clinica Medica", Gabriele d'Annunzio University of Chieti and Pescara, Chieti, Italy. (4)Research Unit of Immunorheumatology, Department of Medicine and Surgery, University Campus Bio-Medico di Roma, Rome, Italy. (5)Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Via Massarenti N. 9, 40138, Bologna, Italy. Metabolically associated fatty liver disease (MASLD) is highly prevalent among individuals with obesity and type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP1-RA) and glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide (GLP1-RA/GIP) dual agonists have demonstrated favorable effects on liver health. Liver steatosis and stiffness can be noninvasively assessed using transient elastography with Fibroscan®. However, evidence regarding the impact of incretin therapy on these elastographic outcomes remains inconsistent across available studies. Indeed, we performed a systematic review and meta-analysis of randomized-controlled trials and case-control studies, which aimed to investigate the effect of GLP1-RA or GLP1-RA/GIP on liver stiffness and steatosis evaluated with Fibroscan® (PROSPERO registration number CRD420251162316). We searched PubMed, Web of Science, and Scopus for English-language studies till March 2025. Methodological quality of the studies was assessed by the Newcastle-Ottawa Scale or Jadad score. In the presence of heterogeneity, standardized (Std) mean differences with 95% confidence intervals (CIs) were combined using a random effect model. Funnel plot and trim-and-fill analysis were used to assess publication bias. Five studies were included in the analysis, accounting for 9 trials. A total of 554 patients and 270 controls were enrolled. The analysis revealed an improvement for both liver stiffness [std. mean difference = - 0.3, 95%CI - 0.5 to - 0.1, p = 0.02] and liver steatosis [std. mean difference = - 0.4, 95%CI - 0.7 to - 0.1, p = 0.03] at the end of the trial. Our findings showed that treatment with GLP1-RA and GLP1-RA/GIP in people with MASLD improves liver stiffness and steatosis evaluated through Fibroscan®. © 2026. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI). Conflict of interest statement: Declarations. Conflict of interest: The authors have no conflicts of interest to declare. Human and animal rights: Not applicable. Informed consent: Not applicable.”
Short answer: yes. The analysis found consistent improvements in both liver stiffness (standardized mean difference -0.3) and steatosis (standardized mean difference -0.4) compared to controls. That’s not a miracle cure, but it’s a measurable move in the right direction for a condition that’s notoriously tough to address.
Key takeaway: Researchers working with GLP-1 agonists or dual GLP-1/GIP agonists can point to meta-analyzed evidence that these compounds shift liver health markers in MASLD. The signal is clear—these peptides do more than just tweak blood sugar.
Details worth noting:
The studies included were all randomized trials or case-controls, boosting confidence in the findings.
Liver stiffness and fat reduction were measured with Fibroscan, a noninvasive and widely used elastography tool.
The meta-analysis ran quality checks for bias and publication reliability.
For anyone interested in the technical side of peptide effects on liver health, this is a solid data point to reference. If you’re exploring the broader world of GLP-1, GIP, and related compounds, check the peptide research index for more context or hit up the vendor directory to see who’s supplying these research peptides.
The bottom line: GLP-1 and dual GLP-1/GIP peptides are earning their place in metabolic and liver research, and Fibroscan data is backing it up.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.